NB-003 is under clinical development by NewBay Medical Technology and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I drugs for Metastatic Melanoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NB-003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NB-003 is under development for the treatment of advanced solid tumors including gastrointestinal stromal tumor (GIST), metastatic melanoma. It is administered through oral route as tablet.
For a complete picture of NB-003’s drug-specific PTSR and LoA scores, buy the report here.